Treatment
Doxorubicin clinical trials
We’re tracking 186 recruiting studies that include Doxorubicin, each written for real people, not researchers, below.
Recruiting studies
- NCT07634471RecruitingPhase 2/Phase 3
Testing MK-1045 and Rituximab for Untreated Follicular Lymphoma
This trial tests a new drug called MK-1045 combined with rituximab (a standard lymphoma treatment) in people who have never been treated for follicular lymphoma. The goal is to see if this combination works better than current treatments.
Durham, North CarolinaAges 18 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Scottsdale, ArizonaAges 18 years+ - NCT07021989RecruitingPhase 2
ctDNA-Guided Therapy for Relapsed Hodgkin Lymphoma
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
Davis, CaliforniaAges 18 years+ - NCT04803201RecruitingPhase 2
Adding new drugs to usual treatment for peripheral T-cell lymphoma
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
Little Rock, ArkansasAges 18 years+ - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT07227584RecruitingPhase 2
ALL treatment for adolescents and young adults
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Boston, MassachusettsAges 18–51 - NCT06843447RecruitingPhase 1/Phase 2
Study of Raludotatug Deruxtecan for Ovarian Cancer
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT07060807RecruitingPhase 3
Study of Patritumab Deruxtecan for Advanced HR+/HER2- Breast Cancer
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Daphne, AlabamaAges 18 years+ - NCT07604766RecruitingPhase 3
Rina-S for platinum-resistant ovarian cancer in China
This study tests a new cancer drug called Rina-S (an antibody-drug conjugate, which is a targeted therapy that delivers medicine directly to cancer cells) compared to standard treatment options for ovarian cancer that has returned or worsened after platinum chemotherapy. The trial is specifically for patients in China whose cancer is resistant to platinum drugs.
ChangchunAges 18 years+ - NCT04307576RecruitingPhase 3
Study for newly diagnosed ALL children and young adults
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
BrusselsAges birth–45 years - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Birmingham, AlabamaAges 5–60 - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT05600686RecruitingPhase 2
New treatment plan for high-risk aggressive lymphoma
This Phase 2 study tests a treatment sequence for people with high-risk diffuse large B-cell lymphoma (DLBCL) that includes loncastuximab plus rituximab, then DA-EPOCH-R. It aims to improve responses in patients whose lymphoma has specific high-risk features.
Sacramento, CaliforniaAges 18 years+ - NCT06647953RecruitingPhase 3
Testing a standard approach for pleuropulmonary blastoma, with or without topotecan
This trial compares a standard surgery and chemotherapy plan for type I pleuropulmonary blastoma (PPB) to adding the drug topotecan for types II and III PPB. The goal is to see if the extra drug helps shrink tumors and improve outcomes for children with more advanced disease.
Birmingham, AlabamaAges Up to 21 years - NCT06563245RecruitingPhase 2/Phase 3
Brentuximab vedotin for Hodgkin lymphoma in children and young adults
This trial tests the drug brentuximab vedotin for children and young adults (ages 2 to under 35) who have just been diagnosed with classical Hodgkin lymphoma. The treatment is guided by PET/CT scans to see how well it works.
ShanghaiAges 2–35 - NCT06524583RecruitingPhase 2
Chemotherapy after surgery for high-risk uterine leiomyosarcoma
This trial tests whether chemotherapy after surgery can help prevent uterine leiomyosarcoma from coming back in patients who are at high risk based on a genetic test of their tumor. It is for women with early-stage cancer (stage I) who have had complete surgery.
AngersAges 18–75 - NCT04745949RecruitingPhase 2
Testing first-line antibody plus immunotherapy for mediastinal lymphoma
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Houston, TexasAges 18 years+ - NCT04432714RecruitingPhase 1/Phase 2
Lenalidomide plus R-DA-EPOCH for MYC-rearranged lymphoma
This early-phase study tests whether lenalidomide combined with R-DA-EPOCH can treat untreated diffuse large B-cell lymphoma (DLBCL) that has a MYC rearrangement. It may help control the lymphoma, but it’s also designed to find the safest and most effective dosing.
Nanjing, JiangsuAges 18–60 - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT01419561RecruitingPhase 2
Studying KSHV inflammatory syndrome (KICS)
This study tracks people with KICS, a condition caused by KSHV (a virus related to Kaposi sarcoma). It aims to understand the syndrome better and may lead to future treatments.
Bethesda, MarylandAges 18 years+ - NCT02797717Recruiting
Treatment study for classical Hodgkin lymphoma in young people
This trial looks at a treatment approach for children and adolescents with classical Hodgkin lymphoma. It may help by testing how well the treatment controls the cancer and is tolerable in young patients.
Petah TikvaAges 1 month–18 years - NCT06745076RecruitingPhase 2
Using a blood test to safely lower chemo for advanced Hodgkin lymphoma
This trial studies whether a blood test (ctDNA) can help doctors safely reduce chemotherapy for people with advanced Hodgkin lymphoma. If you have stage 3 or 4 Hodgkin lymphoma that hasn't been treated yet and are healthy enough for strong chemo, this study may be an option for you.
Irvine, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Doxorubicin?
- Yes. Clin2 currently lists 186 recruiting studies that include Doxorubicin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Doxorubicin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Doxorubicin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Doxorubicin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.